NAUT
NASDAQ · Life Sciences Tools & Services
Nautilus Biotechnology Inc
$3.48
-0.30 (-7.94%)
Financial Highlights (FY 2025)
Revenue
80.17M
Net Income
11.70M
Gross Margin
61.0%
Profit Margin
14.6%
Rev Growth
+16.9%
D/E Ratio
0.11
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 61.0% | 61.0% | 61.0% |
| Operating Margin | 18.2% | 15.8% | 18.6% |
| Profit Margin | 14.6% | 13.0% | 15.2% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 80.17M | 80.92M | 67.58M |
| Gross Profit | 48.91M | 49.37M | 41.23M |
| Operating Income | 14.59M | 12.80M | 12.55M |
| Net Income | 11.70M | 10.54M | 10.24M |
| Gross Margin | 61.0% | 61.0% | 61.0% |
| Operating Margin | 18.2% | 15.8% | 18.6% |
| Profit Margin | 14.6% | 13.0% | 15.2% |
| Rev Growth | +16.9% | +0.2% | +13.7% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 22.23M | 24.81M | 20.67M |
| Total Equity | 203.50M | 205.46M | 185.25M |
| D/E Ratio | 0.11 | 0.12 | 0.11 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 18.12M | 18.88M | 15.83M |
| Free Cash Flow | 8.11M | 11.53M | 7.63M |